InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | 2026-05-28 | VON RICKENBACH JOSEF H | Director | Purchase | 4,500 | $1.07 | $5K | 62.5K | View ↗ | |
| 2026-05-26 | 2026-05-28 | VON RICKENBACH JOSEF H | Director | Purchase | 23.2K | $1.06 | $24K | 58.0K | View ↗ | |
| 2026-05-22 | 2026-05-28 | VON RICKENBACH JOSEF H | Director | Purchase | 15.9K | $1.05 | $17K | 34.8K | View ↗ | |
| 2026-05-21 | 2026-05-28 | VON RICKENBACH JOSEF H | Director | Purchase | 3,420 | $1.04 | $4K | 18.9K | View ↗ | |
| 2026-04-30 | 2026-05-13 | WINDSOR JAMES BRIAN | Director & See Remarks | Purchase | 25.0K | $1.00 | $25K | 27.0K | View ↗ |
No annual data found.
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rein Therapeutics stock dips after pricing $50M share offering
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis